Andrés Belmonte, Amado Calvo, Natividad González Monte, Esther
Impacto de darbepoetina alfa en el manejo de la anemia precoz postrasplante renal: estudio retrospectivo exploratorio. [artículo] - Nefrología : publicación oficial de la Sociedad Española Nefrologia, 2013 - 33(1):107-15.
Formato Vancouver:
Jiménez C, González E, Marqués M, Galeano C, Andrés A, Calvo N, Pascual J. Impacto de darbepoetina alfa en el manejo de la anemia precoz postrasplante renal: estudio retrospectivo exploratorio. Nefrologia. 2013 Jan 18;33(1):107-15.
PMID: 23364633
Contiene 32 referencias
Background and objectives: The use of darbepoetin alfa in the first week of post-renal transplant (RT). Methods: Retrospective observational study carried out in four hospitals, which included all adult patients that underwent RT for 9 months with haemoglobin data during the first 6 months of post-transplant (n = 129). Darbepoetina alfa was administered in accordance with the clinical practice. Results: darbepoetin alfa was administered in the first week to 60 individuals (46.5%), who had a mean baseline Hb (+/- standard deviation) of 12.7g/dl +/- 1.6g/dl. Anaemia incidence (Hb < 11g/dl) during the first month was higher in patients who did not receive darbepoetin alfa (40.6% vs. 25.0% in patients treated with darbepoetin alfa, P=.045). No anaemia incidence differences were observed during months +2 to +6. There was a tendency towards transfusion decrease in patients who received darbepoetin alfa (13.3% vs. 20.3%, P=.295). Renal recovery time was similar but in the subgroup which received grafts from donors with asystole there was a tendency towards a faster recovery with darbepoetin alfa (15.1 +/- 7.7 vs. 20.1 +/- 8.8 days, P=.157). The creatinine clearance rate at 3 and 6 months was similar. Fourteen patients (10.9%) suffered from cardiovascular events with no relation to darbepoetin alfa (P=.772). Conclusions: Administering darbepoetin alfa in the first week following renal transplant reduces anaemia incidence during the first month without increase cardiovascular events.
Impacto de darbepoetina alfa en el manejo de la anemia precoz postrasplante renal: estudio retrospectivo exploratorio. [artículo] - Nefrología : publicación oficial de la Sociedad Española Nefrologia, 2013 - 33(1):107-15.
Formato Vancouver:
Jiménez C, González E, Marqués M, Galeano C, Andrés A, Calvo N, Pascual J. Impacto de darbepoetina alfa en el manejo de la anemia precoz postrasplante renal: estudio retrospectivo exploratorio. Nefrologia. 2013 Jan 18;33(1):107-15.
PMID: 23364633
Contiene 32 referencias
Background and objectives: The use of darbepoetin alfa in the first week of post-renal transplant (RT). Methods: Retrospective observational study carried out in four hospitals, which included all adult patients that underwent RT for 9 months with haemoglobin data during the first 6 months of post-transplant (n = 129). Darbepoetina alfa was administered in accordance with the clinical practice. Results: darbepoetin alfa was administered in the first week to 60 individuals (46.5%), who had a mean baseline Hb (+/- standard deviation) of 12.7g/dl +/- 1.6g/dl. Anaemia incidence (Hb < 11g/dl) during the first month was higher in patients who did not receive darbepoetin alfa (40.6% vs. 25.0% in patients treated with darbepoetin alfa, P=.045). No anaemia incidence differences were observed during months +2 to +6. There was a tendency towards transfusion decrease in patients who received darbepoetin alfa (13.3% vs. 20.3%, P=.295). Renal recovery time was similar but in the subgroup which received grafts from donors with asystole there was a tendency towards a faster recovery with darbepoetin alfa (15.1 +/- 7.7 vs. 20.1 +/- 8.8 days, P=.157). The creatinine clearance rate at 3 and 6 months was similar. Fourteen patients (10.9%) suffered from cardiovascular events with no relation to darbepoetin alfa (P=.772). Conclusions: Administering darbepoetin alfa in the first week following renal transplant reduces anaemia incidence during the first month without increase cardiovascular events.